Benzinga | Oct 11, 2021 04:08PM EDT

Inhibrx To Host Webcast Presentation Of Interim Results From The Phase 1 Trial Of INBRX-101, Its Recombinant Human AAT-Fc Protein For The Treatment Of Alpha-1 Antitrypsin Deficiency

Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced that it will host a live webcast presentation on Tuesday, October 12, 2021, at 5:30 a.m. PT to provide interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101 in patients with alpha-1 antitrypsin deficiency, or AATD.